ValiRx plc
VAL.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | £0 | £0 | £0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | – | £0 | £0 | £0 |
| Gross Profit | – | -£0 | -£0 | -£0 |
| % Margin | – | -166.8% | – | -1,331.5% |
| R&D Expenses | – | £0 | £0 | £0 |
| G&A Expenses | – | £0 | £0 | £0 |
| SG&A Expenses | – | £1 | £1 | £1 |
| Sales & Mktg Exp. | – | £0 | £0 | £0 |
| Other Operating Expenses | – | £0 | £0 | £0 |
| Operating Expenses | – | £1 | £1 | £1 |
| Operating Income | – | -£1 | -£1 | -£1 |
| % Margin | – | -2,177% | – | -11,950.2% |
| Other Income/Exp. Net | – | £0 | £0 | -£0 |
| Pre-Tax Income | – | -£1 | -£1 | -£1 |
| Tax Expense | – | -£0 | -£0 | -£0 |
| Net Income | – | -£1 | -£1 | -£1 |
| % Margin | – | -1,898.1% | – | -10,440.4% |
| EPS | – | -0.007 | -0.007 | -0.01 |
| % Growth | – | 4.1% | 24.5% | – |
| EPS Diluted | – | -0.007 | -0.007 | -0.01 |
| Weighted Avg Shares Out | – | 132 | 131 | 102 |
| Weighted Avg Shares Out Dil | – | 132 | 131 | 102 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | £0 | £0 | £0 |
| Interest Expense | – | £0 | £0 | £0 |
| Depreciation & Amortization | – | £0 | £0 | £0 |
| EBITDA | – | -£1 | -£1 | -£1 |
| % Margin | – | -1,837.5% | – | -10,533.7% |